SG11201810465RA - Compositions and methods related to engineered fc constructs - Google Patents

Compositions and methods related to engineered fc constructs

Info

Publication number
SG11201810465RA
SG11201810465RA SG11201810465RA SG11201810465RA SG11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA
Authority
SG
Singapore
Prior art keywords
massachusetts
international
street
rule
constructs
Prior art date
Application number
SG11201810465RA
Inventor
Jonathan C Lansing
Carlos J Bosques
Daniel Ortiz
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of SG11201810465RA publication Critical patent/SG11201810465RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 1111111101011111011010111100111111111110111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/205436 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: RUTITZKY, Laura; 70 Clarendon Avenue, Somerville, C07K 16/28 (2006.01) C07K 16/46 (2006.01) Massachusetts 02144 (US). SCHULTES, Birgit C.; 12 (21) International Application Number: Monadnock Road, Arlington, Massachusetts 02476 (US). PCT/US2017/034087 (74) Agent: MEIKLEJOHN, PH.D., Anita L.; Fish & Richard- (22) International Filing Date: son P.C., P. 0. Box 1022, Minneapolis, Minnesota 55440-1022 (US). 23 May 2017 (23.05.2017) (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/340,322 23 May 2016 (23.05.2016) US DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, 62/443,451 06 January 2017 (06.01.2017) US HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: MOMENTA PHARMACEUTICALS, INC. MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, [US/US]; 675 West Kendall Street, Cambridge, Massachu- PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, setts 02142 (US). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: LANSING, Jonathan C.; 220 Woburn Street, Reading, Massachusetts 01867 (US). BOSQUES, Car- (84) Designated States (unless otherwise indicated, for every _ los J.; 40 Brattle Street, Apt. 7, Arlington, Washington kind of regional protection available): ARIPO (BW, GH, 02476 (US). HUSTON, James S.; 270 Pleasant Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = #A206, Waterton, Massachusetts 02472 (US). LING, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Leona E.; 45 Fells Road, Winchester, Massachusetts TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = 01890 (US). MEADOR III, James; 38 Gryzboska Circle, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — Framingham, Massachusetts 01702 (US). ORTIZ, Daniel; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 15 High Street, Stoneham, Massachusetts 02180 (US). = = — (54) Title: COMPOSITIONS AND METHODS RELATED = = = 1200 = = = = — = = = • = T = :P. xte J TO ENGINEERED Platelet Levels a Day normst FC S mar CONSTRUCTS 1-1 .4 e en 7r kin ei IN 4\" st,\" FIG. 16 1-1 © (57) : The present disclosure relates to compositions and methods of engineered IgG Fc constructs, wherein the Fc constructs ei include one or more Fc domains. [Continued on next page] WO 2017/205436 Al MIDEDIMOMOIDEIROIDEMODIMIRINIMIMMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201810465RA 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs SG11201810465RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US201762443451P 2017-01-06 2017-01-06
PCT/US2017/034087 WO2017205436A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
SG11201810465RA true SG11201810465RA (en) 2018-12-28

Family

ID=60412547

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201810466PA SG11201810466PA (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs
SG10202011624SA SG10202011624SA (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs
SG11201810465RA SG11201810465RA (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201810466PA SG11201810466PA (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs
SG10202011624SA SG10202011624SA (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Country Status (13)

Country Link
US (4) US11155640B2 (en)
EP (2) EP3464376A4 (en)
JP (4) JP7045333B6 (en)
KR (3) KR102590061B1 (en)
CN (3) CN116063540A (en)
AU (2) AU2017272111A1 (en)
BR (2) BR112018074056A2 (en)
CA (2) CA3025310A1 (en)
DK (1) DK3484514T3 (en)
IL (3) IL263213B1 (en)
PL (1) PL3484514T3 (en)
SG (3) SG11201810466PA (en)
WO (2) WO2017205436A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941072A1 (en) * 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
IL263213B1 (en) 2016-05-23 2024-01-01 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CA3049383A1 (en) 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
MX2021000287A (en) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc-antigen binding domain constructs.
EP3820910A4 (en) * 2018-07-11 2022-06-22 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
WO2020014413A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
WO2020014526A2 (en) * 2018-07-11 2020-01-16 Anthony Manning Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
JP2021530992A (en) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド Compositions and Methods for Modified Fc Antigen Binding Domain Constructs
CA3106108A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
CA3106256A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
KR20210042324A (en) * 2018-07-11 2021-04-19 모멘타 파머슈티컬스 인코포레이티드 Compositions and methods related to CCR4 targeting engineered Fc-antigen binding domain constructs
KR102661494B1 (en) 2019-03-08 2024-04-29 에이치엘만도 주식회사 Rack Assist Type Electric Power Steering Apparatus
JP2022547692A (en) 2019-09-13 2022-11-15 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Recombinant IgG Fc Multimers for Treatment of Immune Complex-Mediated Kidney Injury
BR112022010096A2 (en) 2019-12-06 2022-09-06 CSL Behring Lengnau AG STABLE COMPOSITIONS OF FC MULTIMERS
CN111808170A (en) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 Polypeptide, HLA-DR protein, preparation method and application thereof
MX2023006639A (en) * 2020-12-07 2023-08-16 Invetx Inc Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (en) 1983-12-07 1987-06-26 Merieux Inst NEW IMMUNOMODULATOR DRUG BASED ON HUMAN IGG FC FRAGMENTS
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0975355A2 (en) 1996-06-14 2000-02-02 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003518075A (en) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド Methods and compositions for extending the elimination half-life of bioactive compounds
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
AR063384A1 (en) * 2006-10-25 2009-01-28 Amgen Inc THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
BRPI0620639A2 (en) 2006-12-21 2011-11-22 Micromet Ag bispecific single chain antibodies and pharmaceutical composition comprising the same
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2641913B1 (en) 2007-06-01 2018-04-18 University of Maryland, Baltimore Immunoglobulin constant region Fc receptor binding agents
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2720368C (en) 2008-04-02 2017-08-22 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US20120064008A1 (en) 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
JP2012527473A (en) 2009-05-20 2012-11-08 セラクローン サイエンシーズ， インコーポレイテッド Compositions and methods for the treatment and diagnosis of influenza
EP2448972A4 (en) 2009-06-30 2012-11-28 Res Dev Foundation Immunoglobulin fc polypeptides
CN104945509A (en) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP2013511281A (en) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド Monomeric antibody Fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EP2591006B1 (en) 2010-07-09 2019-04-24 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
TWI588157B (en) 2010-07-28 2017-06-21 吉林尼克公司 Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
MX347077B (en) * 2010-12-23 2017-04-10 Janssen Biotech Inc Active protease-resistant antibody fc mutants.
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
EA201791693A1 (en) 2011-03-25 2018-05-31 Гленмарк Фармасьютикалс С.А. HETERODIMERNY IMMUNOHLOBULINS
EP2858659B1 (en) * 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015531748A (en) 2012-06-21 2015-11-05 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Incretin receptor ligand polypeptide FC region fusion polypeptide and complex having modified FC effector function
MX2015002269A (en) * 2012-08-20 2015-07-06 Gliknik Inc Molecules with antigen binding and polyvalent fc gamma receptor binding activity.
EP2908914B1 (en) 2012-10-17 2018-04-18 Liverpool School of Tropical Medicine Immunomodulatory proteins
CN104558194B (en) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015107025A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
AU2015226100B2 (en) 2014-03-05 2020-05-07 UCB Biopharma SRL Multimeric Fc proteins
BR112016020377A2 (en) 2014-03-05 2018-01-23 Ucb Biopharma Sprl multimeric fc proteins
CA2941072A1 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EP3148580B1 (en) * 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
IL263213B1 (en) 2016-05-23 2024-01-01 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CA3049383A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Also Published As

Publication number Publication date
JP7045333B2 (en) 2022-03-31
SG10202011624SA (en) 2021-01-28
CA3025310A1 (en) 2017-11-30
JP7045333B6 (en) 2022-05-06
SG11201810466PA (en) 2018-12-28
US20240067757A1 (en) 2024-02-29
WO2017205436A1 (en) 2017-11-30
US11155640B2 (en) 2021-10-26
US20190284305A1 (en) 2019-09-19
US20210221917A1 (en) 2021-07-22
US20220049019A1 (en) 2022-02-17
IL263213B1 (en) 2024-01-01
CN109963869A (en) 2019-07-02
IL263211B2 (en) 2023-09-01
KR102635635B1 (en) 2024-02-14
IL263211A (en) 2018-12-31
IL309293A (en) 2024-02-01
US11623964B2 (en) 2023-04-11
CN109789203B (en) 2022-08-05
CN116063540A (en) 2023-05-05
BR112018074056A2 (en) 2019-03-06
PL3484514T3 (en) 2024-04-29
EP3464376A4 (en) 2020-03-18
JP2022095685A (en) 2022-06-28
AU2017272111A1 (en) 2019-01-17
KR102462084B1 (en) 2022-11-02
CA3025306A1 (en) 2017-11-30
EP3484514B1 (en) 2023-12-06
EP3464376A1 (en) 2019-04-10
EP3484514A4 (en) 2020-08-12
WO2017205434A1 (en) 2017-11-30
EP3484514A1 (en) 2019-05-22
DK3484514T3 (en) 2024-01-29
IL263211B1 (en) 2023-05-01
BR112018074032A2 (en) 2019-02-26
AU2017272109A1 (en) 2019-01-17
JP7295301B2 (en) 2023-06-20
KR20190021255A (en) 2019-03-05
CN109789203A (en) 2019-05-21
JP2022068176A (en) 2022-05-09
KR20220151025A (en) 2022-11-11
JP2019519528A (en) 2019-07-11
IL263213A (en) 2018-12-31
JP2019519527A (en) 2019-07-11
KR20190026684A (en) 2019-03-13
KR102590061B1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
SG11201810465RA (en) Compositions and methods related to engineered fc constructs
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201811189RA (en) Variant adeno-associated viruses and methods of using
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201806404SA (en) Systems and methods for storing and sharing transactional data using distributed computer systems
SG11201909949XA (en) Targeted immunotolerance
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201804721SA (en) Modulators of complement activity
SG11201906139VA (en) Compositions and methods related to engineered fc constructs